이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Integrum 대차 대조표 상태

재무 상태 기준 확인 6/6

Integrum 의 총 주주 지분은 SEK142.9M 이고 총 부채는 SEK0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 SEK165.0M 및 SEK22.1M 입니다. Integrum 의 EBIT는 SEK691.0K 이며 이자보상배율은 1.5 입니다. SEK16.9M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

SEK 0

부채

이자 보상 비율	1.5x
현금	SEK 16.90m
주식	SEK 142.93m
총 부채	SEK 22.07m
총 자산	SEK 165.00m

최근 재무 상태 업데이트

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

May 03

Recent updates

재무 상태 분석

단기부채: INTEG B 의 단기 자산 ( SEK79.6M )이 단기 부채( SEK17.2M ).

장기 부채: INTEG B 의 단기 자산( SEK79.6M )이 장기 부채( SEK4.8M ).

부채 대 자본 내역 및 분석

부채 수준: INTEG B 부채가 없습니다.

부채 감소: INTEG B 는) 부채 대 자기자본 비율이 8.8% 였던 5년 전과 비교하여 부채가 없습니다.

부채 범위: INTEG B 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: INTEG B 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Integrum 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

Recent updates

Consensus EPS estimates fall by 37%, revenue upgraded

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Price target increased by 7.3% to kr77.25

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

Less than half of directors are independent

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023

Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations

Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations

New minor risk - Profitability

Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing

Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI

Integrum Receives Unitary Patent for Neuromotus in the EU

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum Initiates A Strategic Review Process to Accelerate Growth

Integrum AB Receives Reimbursement Code for Axor II

Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand

Integrum AB (Publ) Announces Management Changes

Consensus revenue estimates decrease by 12%

Price target decreased by 31% to kr72.00

New minor risk - Share price stability

Full year 2023 earnings: Revenues miss analyst expectations

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Consensus revenue estimates decrease by 40%

Third quarter 2023 earnings released

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Consensus forecasts updated

Second quarter 2023 earnings released

Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and Neuromotus

Less than half of directors are independent

Investor sentiment improved over the past week

Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade Organization

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Does Integrum (STO:INTEG B) Deserve A Spot On Your Watchlist?

First quarter 2023 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released

Integrum AB (publ) to Report Q2, 2023 Results on Dec 05, 2022

Integrum AB (publ) Announces Board Changes

Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical Officer

Price target decreased to kr100.00

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022

Investor sentiment deteriorated over the past week

Owner & Chairman exercised options to buy kr1.4m worth of stock.

Investor sentiment improved over the past week

Integrum's (STO:INTEG B) Earnings Aren't As Good As They Appear

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast to breakeven in 2023

First quarter 2022 earnings released

Full year 2021 earnings released: kr0.038 loss per share (vs kr1.04 loss in FY 2020)

Introducing Integrum (STO:INTEG B), The Stock That Soared 873% In The Last Year

Art Clinic, Center of Excellence in the Nordic countries, has treated its first patient with Integrum's OPRA™ Implant System

Third quarter 2021 earnings released

BG Klinik Tübingen to Treat Thumb Amputees with Integrum's OPRA Implant System

Integrum AB Collaboration with Onkos Pave the Way for Further Growth in the US